PUBLIC COMPANY
save$AMLXAmylyx Pharmaceuticals, Inc.
$AMLX39.66+2.75%Cambridge, MA, USupdated 15h ago
Amylyx Pharmaceuticals, Inc is a biopharmaceutical company headquartered in Cambridge, Massachusetts. Amylyx is best known for AMX0035, an experimental therapy for amyotrophic lateral sclerosis. AMX0035 was approved for medical use in Canada as Albrioza, in June 2022, and in the United States, as Relyvrio, in September 2022. It was withdrawn in April, 2024.
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(3)
pipeline depth3 products
1Phase 11Phase 21Phase 3
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Active trials
- —An Expanded Access Protocol to Provide Avexitide in Patients With Post-Bariatric Hypoglycemia
- phase1AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis
- phase2AMX0035 in Adult Patients With Wolfram Syndrome
- phase3Avexitide for Treatment of Post-Bariatric Hypoglycemia
- phase2Open Label Extension Study of AMX0035 in Patients With ALS
- phase2Study to Assess the Safety and Biological Activity of AMX0035 for the Treatment of Alzheimer's Disease
- phase3Extension Study Evaluating The Safety And Tolerability of AMX0035
- phase3AMX0035 and Progressive Supranuclear Palsy
Insider activity
source: SEC Form 4open-market buys + sells
- Mar 2, 26SELLCohen Joshua B· Co-Chief Executive Officer−$424K↗
- Mar 2, 26SELLKlee Justin B.· Co-Chief Executive Officer−$424K↗
- Mar 2, 26SELLFRATES JAMES M· Chief Financial Officer−$115K↗
- Mar 2, 26SELLMazzariello Gina· Chief Legal Officer−$99K↗
- Mar 2, 26SELLBedrosian Camille L· Chief Medical Officer−$94K↗
- Feb 23, 26SELLMazzariello Gina· Chief Legal Officer−$48K↗
routine RSU / option mechanics (6)
- Mar 5, 26grantKlee Justin B. · Co-Chief Executive Officer248,865 sh
- Mar 5, 26grantKlee Justin B. · Co-Chief Executive Officer373,295 sh
- Mar 5, 26grantCohen Joshua B · Co-Chief Executive Officer248,865 sh
- Mar 5, 26grantBedrosian Camille L · Chief Medical Officer143,985 sh
- Mar 5, 26grantBedrosian Camille L · Chief Medical Officer95,990 sh
- Mar 5, 26grantCohen Joshua B · Co-Chief Executive Officer373,295 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
- STAT+: The biotech scorecard for the third quarter: 15 stock-moving events to watchHere is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third quarter.stat · 1mo ago
Data sources
last refreshed 6m ago
Found something off?
comments(0)
5-min edit window · permanent after that